August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Amol Akhade: Avutometinib + Defactinib in Recurrent LGSOC
Jul 15, 2025, 18:31

Amol Akhade: Avutometinib + Defactinib in Recurrent LGSOC

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X about a recent study by Susana N. Banerjee et al. published in JCO:

“New JCO Study: ENGOT-OV60/RAMP 201

Avutometinib (MEK1/2 inh) + Defactinib (FAK inh) in recurrent LGSOC

Dual MAPK + FAK blockade = tumor + stroma suppression

Efficacy:

  • ORR 31% overall
  • 44% in KRAS-mut vs 17% WT
  • PFS: 22.0 mo (KRAS-mut), 12.8 mo (WT)
  • DOR: 31.1 mo

KRAS-mutant tumors = MAPK addicted = better MEK+FAK response

Responses even post-MEKi!”

Title: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Journal: JCO

Authors: Susana N. Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley J. Monk, Andrew Clamp, Emily Prendergast, Ana Oaknin, Kari Ring, Nicoletta Colombo, Robert W. Holloway, Manuel Rodrigues, Hye Sook Chon, Charlie Gourley, Alessandro D. Santin, Premal H. Thaker, Christine Gennigens, Gregg Newman, Erin Salinas, Hagop Youssoufian, Kathleen N. Moore, Stephanie Lustgarten, David M. O’Malley, Toon Van Gorp, Rachel N. Grisham

Read the full article.

Amol Akhade

More posts featuring Amol Akhade on OncoDaily.